



1647

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	<b>Application Number</b>	09/800,103	
	<b>Filing Date</b>	March 6, 2001	
	<b>First Named Inventor</b>	Donoho, Gregory	
	<b>Group Art Unit</b>	1647	
	<b>Examiner Name</b>	R. Landsman	
<b>Total Number of Pages in This Submission</b>	8	<b>Attorney Docket Number</b>	LEX-0143-USA

RECEIVED  
JUL 9 2002  
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input checked="" type="checkbox"/> Amendment/Response (Restriction)  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition  <input type="checkbox"/> To Convert a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Small Entity Statement  <input type="checkbox"/> Request of Refund	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communications to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communications to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): return postcard
<b>Remarks</b>		 <b>24231</b> PATENT TRADEMARK OFFICE

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
<b>Firm or Individual name</b>	Lance K. Ishimoto, Reg. No. 41,866 Lexicon Genetics Incorporated
<b>Signature</b>	 Peter G. Seferian Reg No 40162
<b>Date</b>	June 26, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202 on this date: June 26, 2002			
<b>Typed or printed name</b>	Nancy Stacey		
<b>Signature</b>		<b>Date</b>	June 26, 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

JUL 9 2002

RECEIVED

#10k  
NB  
07/10/02

Applicant(s):	Donoho et al.	Group Art Unit: 1647
Application No.:	09/800,103	Examiner: R. Landsman
Filed:	March 6, 2001	Attorney Docket No.: LEX-0143-USA
Title:	Novel Human Transporter Proteins and Polynucleotides Encoding the Same	

**AMENDMENT; RESPONSE TO RESTRICTION AND ELECTION REQUIREMENTS DATED MAY 30, 2002**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

The Examiner is respectfully requested to enter the following amendments. A response to the Restriction and Election Requirement dated May 30, 2002 (Paper No. 9) is also included herewith, and the Examiner is respectfully requested to consider the remarks therein

**AMENDMENT**

**In the claims:**

Please cancel claims 4-12, entirely without prejudice and without disclaimer, as drawn to non-elected inventions.

Please amend claim 2 so that the text of the amended claim reads as follows:

2. (Amended) An isolated nucleic acid molecule comprising a nucleotide sequence that:
- (a) encodes the amino acid sequence of SEQ ID NO:2; and
  - (b) hybridizes under highly stringent conditions to the nucleotide sequence of SEQ ID NO:1 or the complement thereof.

Please add new claims 13 and 14 as follows:

1. -13.(New) A recombinant expression vector comprising the isolated nucleic acid molecule of claim

Q2  
Cord

14. (New) A host cell comprising the recombinant expression vector of claim 13.--

---

## **RESPONSE**

### **I. Restriction Requirement**

The Examiner has determined that the original claims are directed to eight separate and distinct inventions under 35 U.S.C. § 121, as follows:

- Group I: Claims 1-3, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:1, or encoding SEQ ID NO:2, classified in class 536, subclass 23.5.
- Group II: Claim 4, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:11, or encoding SEQ ID NO:12, classified in class 536, subclass 23.5.
- Group III: Claim 5, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:37, classified in class 536, subclass 23.5.
- Group IV: Claim 6, said to be drawn to an isolated oligopeptide comprising at least 12 amino acids of SEQ ID NO:38, classified in class 530, subclass 300.
- Group V: Claims 7-9, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:13, or encoding SEQ ID NO:14, classified in class 536, subclass 23.5.
- Group VI: Claim 10, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:23, or encoding SEQ ID NO:24, classified in class 536, subclass 23.5.
- Group VII: Claim 11, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:25, classified in class 536, subclass 23.5.
- Group VIII: Claim 12, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:26, classified in class 536, subclass 23.5.

### **II. Response to Restriction and Election Requirement**

In response to the Restriction Requirement mailed May 28, 2002 ( Paper No. 9), and in compliance with 37 CFR 1.1.43, Applicants elect without traverse to prosecute the claims of Group I comprising Claims 1-3, said to be drawn to an isolated nucleic acid molecule related to SEQ ID NO:1,